BioWorld Asia

Jan. 9, 2008

Addex, Merck Ink $702M Deal for Schizophrenia Compound

Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International) Read More

NicOx Renews Research Deal with Pfizer in Ophthalmology

Gene Variant Could Provide Clues to the Cause of ALS

Silence Tries to Calm Investors After Share Price Takes a Dive

EMA Promises to Boost Professionalism in 2008

Faust Signs Research Deal with Takeda for GPCRs

Sepracor Enters $175M Deal with Bial for Epilepsy Drug

Biotech Industry Welcomes EU Support for its Products

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...